Rituximab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Rituximab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
2660
Registered trials
2887
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Rituximab can convert its Monoclonal antibody profile and CD20 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Rituximab (query alias: rituximab) |
|---|---|
| Modality / target | Monoclonal antibody; CD20; CD20 inhibitors, ADCC, CD20-directed cytolytic effects |
| Highest global status | Approved |
| Originator | Genentech, Inc. |
| Active developers | Hoffmann-La Roche, Inc., Celgene Corp., Genentech, Inc. |
The MCP disease footprint includes Autoimmune Haemolytic Anaemias, Cardiac transplant rejection, Liver transplant rejection. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07697339 | Phase 1 | Not yet recruiting | 40 | Phase Ib: Incidence and severity of adverse events |
| NCT07694414 | Phase 1 | Not yet recruiting | 25 | Incidence and severity of rituximab-related adverse events graded according to CTCAE v. 6.0 |
| NCT07703657 | Not Applicable | Not yet recruiting | 168 | Cumulative incidence of clinically significant EBV DNAemia within 180 days after allogeneic hematopoietic stem cell transplantation |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A phase 1 study of R-GDP–venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18)
Phase 1; n=24; evaluation: Positive. Reported fields: AE = The main adverse events were hematologic symptoms, infection, gastrointestinal symptoms, and fatigue. Rates of febrile neutropenia improved after an amendment introducing mandatory granulocyte colony-stimulating factor.
Venetoclax Plus Dose-adjusted R-EPOCH or R-CHOP for Richter's Syndrome
Phase 2; n=69; evaluation: not stated. Reported fields: 3-month Rate of Complete Response (CR) = 0.286 proportion of participants (95% Confidence Interval, 0.16 - 0.448); 3-month Rate of Complete Response (CR) = 0.65 proportion of participants (95% Confidence Interval, 0.41 - 0.85); -
RISK OF HERPES ZOSTER IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES INITIATING BIOLOGIC OR TARGETED SYNTHETIC THERAPIES: A NATIONWIDE COHORT STUDY
Not Applicable; n=342199; evaluation: Positive. Reported fields: HR(weighted analyses): HR = 2.0(95.0% CI, 1.73 - 2.31); HR = 2.4(95.0% CI, 1.9 - 3.0); HR(weighted analyses): HR = 2.0(95.0% CI, 1.73 - 2.31); HR = 2.4(95.0% CI, 1.9 - 3.0); HR(weighted analyses): HR = 2.0(95.0% CI, 1.73 - 2.31); HR = 2.4(95.0% CI, 1.9 - 3.0)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Rituximab addresses Autoimmune Haemolytic Anaemias, Cardiac transplant rejection, Liver transplant rejection. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-04-09 | Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. announced the termination of the co-promotion in Japan for Rituxan® intravenous infusion 100 mg and 500 mg | Approved | Financial terms not disclosed |
| 2025-02-13 | 百洋医药产业化平台再添新品，携手罗氏制药共推经典肿瘤靶向药美罗华®商业化 | Approved | Financial terms not disclosed |
| 1995-03-16 | Genentech and IDEC also entered into a Collaboration Agreement for C2B8 | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Use of bispecific Anti-CD3/CD20 polypeptide complex”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
